Kyle Gano Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Kyle Gano.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Kyle Gano. Kyle Gano is Chief Business Dev Officer in NEUROCRINE BIOSCIENCES INC ($NBIX) and Chief Business Development Off in NEUROCRINE BIOSCIENCES INC ($NBIX) and See Remarks in NEUROCRINE BIOSCIENCES INC ($NBIX).
Latest Insider Trading Transactions of Kyle Gano
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 7,439 | 0 | 7,439 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 117.63 | 44,632 | 5,250,062 | 44,632 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 116.83 | 1,623 | 189,622 | 104,768 | 106.4 K to 104.8 K (-1.53 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 116.83 | 1,000 | 116,826 | 103,306 | 104.3 K to 103.3 K (-0.96 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 116.89 | 1,070 | 125,070 | 102,406 | 103.5 K to 102.4 K (-1.03 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 114.09 | 1,974 | 225,207 | 100,439 | 102.4 K to 100.4 K (-1.93 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 113.77 | 703 | 79,977 | 98,663 | 99.4 K to 98.7 K (-0.71 %) |
| Nov 16 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 90.73 | 2,257 | 204,770 | 98,028 | 100.3 K to 98 K (-2.25 %) |
| Aug 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 118.87 | 2,257 | 268,286 | 95,997 | 98.3 K to 96 K (-2.30 %) |
| Apr 28 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 99.47 | 1,934 | 192,377 | 93,967 | 95.9 K to 94 K (-2.02 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 103.33 | 1,623 | 167,710 | 91,975 | 93.6 K to 92 K (-1.73 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 12,148 | 0 | 12,148 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 102.90 | 76,683 | 7,890,681 | 76,683 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 101.41 | 1,000 | 101,413 | 90,514 | 91.5 K to 90.5 K (-1.09 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 103.08 | 1,974 | 203,482 | 89,614 | 91.6 K to 89.6 K (-2.16 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 103.04 | 703 | 72,433 | 87,838 | 88.5 K to 87.8 K (-0.79 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 103.01 | 1,013 | 104,346 | 87,204 | 88.2 K to 87.2 K (-1.15 %) |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 12,339 | 0 | 12,339 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 81.05 | 66,673 | 5,403,847 | 66,673 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 83.56 | 762 | 63,673 | 85,833 | 86.6 K to 85.8 K (-0.88 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 88.14 | 669 | 58,963 | 84,695 | 85.4 K to 84.7 K (-0.78 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 88.14 | 1,300 | 114,576 | 83,439 | 84.7 K to 83.4 K (-1.53 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 88.05 | 465 | 40,943 | 80,989 | 81.5 K to 81 K (-0.57 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 88.14 | 1,375 | 121,186 | 80,117 | 81.5 K to 80.1 K (-1.69 %) |
| Aug 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.66 | 28,266 | 244,784 | 28,266 | |
| Aug 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 115.00 | 28,266 | 3,250,590 | 78,742 | 107 K to 78.7 K (-26.41 %) |
| Aug 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.66 | 28,266 | 244,784 | 107,008 | 78.7 K to 107 K (+35.90 %) |
| Mar 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.65 | 23,650 | 204,573 | 0 | |
| Mar 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 90.00 | 23,650 | 2,128,500 | 78,742 | 102.4 K to 78.7 K (-23.10 %) |
| Mar 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.65 | 23,650 | 204,573 | 102,392 | 78.7 K to 102.4 K (+30.03 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 15,000 | 0 | 15,000 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 12,250 | 0 | 12,250 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 5,350 | 0 | 5,350 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 81.49 | 30,400 | 2,477,296 | 30,400 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Payment of Exercise | F | 82.48 | 658 | 54,272 | 79,446 | 80.1 K to 79.4 K (-0.82 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 83.19 | 671 | 55,819 | 78,204 | 78.9 K to 78.2 K (-0.85 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 82.98 | 1,375 | 114,095 | 76,950 | 78.3 K to 77 K (-1.76 %) |
| Jan 18 2018 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 79.05 | 1,625 | 128,460 | 74,871 | 76.5 K to 74.9 K (-2.12 %) |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.66 | 13,468 | 116,633 | 0 | |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.65 | 11,350 | 98,178 | 0 | |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 71.05 | 13,468 | 956,901 | 73,246 | 86.7 K to 73.2 K (-15.53 %) |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.66 | 13,468 | 116,633 | 86,714 | 73.2 K to 86.7 K (+18.39 %) |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 71.05 | 11,350 | 806,418 | 73,246 | 84.6 K to 73.2 K (-13.42 %) |
| Nov 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.65 | 11,350 | 98,178 | 84,596 | 73.2 K to 84.6 K (+15.50 %) |
| Oct 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.65 | 20,393 | 176,399 | 35,000 | |
| Oct 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 60.00 | 20,393 | 1,223,580 | 73,246 | 93.6 K to 73.2 K (-21.78 %) |
| Oct 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.65 | 20,393 | 176,399 | 93,639 | 73.2 K to 93.6 K (+27.84 %) |
| Sep 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 8.65 | 4,607 | 39,851 | 55,390 | |
| Sep 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 60.00 | 4,607 | 276,420 | 73,246 | 77.9 K to 73.2 K (-5.92 %) |
| Sep 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 8.65 | 4,607 | 39,851 | 77,853 | 73.2 K to 77.9 K (+6.29 %) |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 2.59 | 15,000 | 38,850 | 0 | |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 54.00 | 15,000 | 810,000 | 73,246 | 88.2 K to 73.2 K (-17.00 %) |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 2.59 | 15,000 | 38,850 | 88,246 | 73.2 K to 88.2 K (+20.48 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 51.23 | 204 | 10,451 | 73,246 | 73.5 K to 73.2 K (-0.28 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 50.41 | 12,861 | 648,323 | 73,450 | 86.3 K to 73.5 K (-14.90 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 7,600 | 0 | 7,600 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 43.24 | 60,000 | 2,594,400 | 60,000 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 43.15 | 727 | 31,370 | 61,311 | 62 K to 61.3 K (-1.17 %) |
| Feb 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 42.57 | 1,375 | 58,534 | 60,113 | 61.5 K to 60.1 K (-2.24 %) |
| Jan 18 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 40.65 | 1,625 | 66,056 | 58,738 | 60.4 K to 58.7 K (-2.69 %) |
| Jan 12 2017 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 43.37 | 1,250 | 54,213 | 57,113 | 58.4 K to 57.1 K (-2.14 %) |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 35.99 | 36,400 | 1,310,036 | 36,400 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 7,700 | 0 | 7,700 | |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 37.98 | 1,375 | 52,223 | 55,863 | 57.2 K to 55.9 K (-2.40 %) |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 5.76 | 39,845 | 229,507 | 0 | |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | M | 5.76 | 1,925 | 11,088 | 39,845 | |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 44.04 | 39,845 | 1,754,774 | 55,863 | 95.7 K to 55.9 K (-41.63 %) |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 43.50 | 1,925 | 83,738 | 95,708 | 97.6 K to 95.7 K (-1.97 %) |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 5.76 | 39,845 | 229,507 | 97,633 | 57.8 K to 97.6 K (+68.95 %) |
| Apr 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Buy | M | 5.76 | 1,925 | 11,088 | 57,788 | 55.9 K to 57.8 K (+3.45 %) |
| Jan 21 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 46.84 | 1,625 | 76,115 | 54,488 | 56.1 K to 54.5 K (-2.90 %) |
| Jan 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 44.23 | 1,250 | 55,288 | 52,863 | 54.1 K to 52.9 K (-2.31 %) |
| Oct 19 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 47.77 | 25,000 | 1,194,250 | 51,613 | 76.6 K to 51.6 K (-32.63 %) |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | See Remarks | Option Exercise | M | 2.59 | 15,000 | 38,850 | 15,000 | |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | See Remarks | Option Exercise | M | 5.76 | 23,230 | 133,805 | 41,770 | |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | See Remarks | Sell | S | 42.19 | 38,230 | 1,612,924 | 26,613 | 64.8 K to 26.6 K (-58.96 %) |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | See Remarks | Buy | M | 2.59 | 15,000 | 38,850 | 64,843 | 49.8 K to 64.8 K (+30.09 %) |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | See Remarks | Buy | M | 5.76 | 23,230 | 133,805 | 49,843 | 26.6 K to 49.8 K (+87.29 %) |
| Feb 05 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | A | 32.99 | 65,000 | 2,144,350 | 65,000 | |
| Feb 05 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | A | 0.00 | 11,000 | 0 | 11,000 | |
| Jan 21 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 30.80 | 1,625 | 50,050 | 26,613 | 28.2 K to 26.6 K (-5.75 %) |
| Jan 15 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | M | 5.76 | 10,000 | 57,600 | 65,000 | |
| Jan 15 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | M | 2.59 | 15,000 | 38,850 | 30,000 | |
| Jan 15 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 30.00 | 25,000 | 750,000 | 24,988 | 50 K to 25 K (-50.01 %) |
| Jan 15 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Buy | M | 5.76 | 10,000 | 57,600 | 49,988 | 40 K to 50 K (+25.01 %) |
| Jan 15 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Buy | M | 2.59 | 15,000 | 38,850 | 39,988 | 25 K to 40 K (+60.03 %) |
| Jan 13 2015 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 28.41 | 1,250 | 35,513 | 24,988 | 26.2 K to 25 K (-4.76 %) |
| Dec 19 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | M | 5.00 | 4,957 | 24,785 | 0 | |
| Dec 19 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 22.50 | 4,957 | 111,533 | 23,738 | 28.7 K to 23.7 K (-17.27 %) |
| Dec 19 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Buy | M | 5.00 | 4,957 | 24,785 | 28,695 | 23.7 K to 28.7 K (+20.88 %) |
| Dec 15 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | M | 5.00 | 4,043 | 20,215 | 4,957 | |
| Dec 15 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 22.50 | 4,043 | 90,968 | 23,738 | 27.8 K to 23.7 K (-14.55 %) |
| Dec 15 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Buy | M | 5.00 | 4,043 | 20,215 | 27,781 | 23.7 K to 27.8 K (+17.03 %) |
| Jan 13 2014 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 18.57 | 1,250 | 23,213 | 23,738 | 25 K to 23.7 K (-5.00 %) |
| Sep 05 2013 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Option Exercise | X | 10.90 | 2,400 | 26,160 | 0 | |
| Sep 05 2013 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Dev ... | Sell | S | 15.61 | 2,400 | 37,464 | 22,488 | 24.9 K to 22.5 K (-9.64 %) |
Page: 1